XORTX shares jump 16.11% after gout drug manufacturing milestone

Verifying
  • XORTX launched production for its XRx-026 gout program.
  • Shares gained 16.11% to $2.45 in Thursday’s after-hours trading.
  • XORTX plans a two-part XRX-OXY-102 study of XORLO™.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.